Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

Australian RCT (n=252) found no difference in Short Form 36 Health Survey Physical Function Score at day 60 in patients treated with nebulised heparin or placebo (mean 53.6 vs 48.7; difference 4.9; 95% CI −4.8 to 14.5]; p=0.32).

The Lancet Respiratory Medicine